Virtu KCG Holdings’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Virtu KCG Holdings’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$485K	Buy	+9,077	New	+$443K	0.01%	1173
2017 Q1	–	Sell	-11,672	Closed	-$466K	–	3131
2016 Q4	$466K	Buy	+11,672	New	+$498K	0.01%	1579
2016 Q2	–	Sell	-9,586	Closed	-$392K	–	2946
2016 Q1	$392K	Buy	9,586 +1,990	+26%	+$88K	0.01%	1445
2015 Q4	$543K	Buy	+7,596	New	+$508K	0.01%	1440
2015 Q3	–	Sell	-6,537	Closed	-$591K	–	3338
2015 Q2	$591K	Buy	+6,537	New	+$562K	0.01%	1342
2014 Q2	–	Sell	-15,408	Closed	-$615K	–	3641
2014 Q1	$615K	Buy	15,408 +2,312	+18%	+$105K	0.01%	1736
2013 Q4	$491K	Buy	+13,096	New	+$438K	0.01%	1980

Other funds holding BIB

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

RIA

RPG Investment Advisory Pleasanton, California $829M AUM 36.68% 1-Year Est. Return

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

PCA

Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BRC

Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return

Virtu KCG Holdings's BIB Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2017: 9,077 shares worth $485K. The stake represents 0.01% of the portfolio and ranks #1173 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in BIB as recently as Q4 2016.

Virtu KCG Holdings first reported a position in BIB in Q4 2013 and has held it in 7 quarters since. The position peaked at $615K in Q1 2014. 32 funds tracked by Wall St. Rank hold BIB as of Q2 2017.

Virtu KCG Holdings held 9,077 shares of ProShares Ultra NASDAQ Biotechnology worth $485K as of Q2 2017.
ProShares Ultra NASDAQ Biotechnology was a new Virtu KCG Holdings position in Q2 2017.
ProShares Ultra NASDAQ Biotechnology made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1173 holding.
Virtu KCG Holdings first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2013 and has held it in 7 quarters since.
Virtu KCG Holdings's ProShares Ultra NASDAQ Biotechnology position peaked at $615K in Q1 2014.
32 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.